ImmunoCellular Therapeutics Ltd (IMUC) Sees Significant Decline in Short Interest
ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the recipient of a significant decline in short interest during the month of December. As of December 29th, there was short interest totalling 2,327,867 shares, a decline of 7.1% from the December 15th total of 2,505,409 shares. Currently, 6.6% of the shares of the company are short sold. Based on an average daily volume of 2,571,251 shares, the short-interest ratio is currently 0.9 days.
ImmunoCellular Therapeutics (NYSEAMERICAN IMUC) opened at $0.31 on Friday. ImmunoCellular Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $3.68. The company has a market cap of $7.37, a price-to-earnings ratio of -0.10 and a beta of 1.03.
COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/14/immunocellular-therapeutics-ltd-imuc-sees-significant-decline-in-short-interest.html.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.
Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.